Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...

On Wednesday, U.K. regulators approved Eli Lilly And Co’s (NYSE:LLY) donanemab, an injection for intravenous infusion to ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...

The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...